BioXcel Reports Positive Phase 3 At-Home Agitation Data
NEW HAVEN, Conn. | May 28, 2026 BioXcel Therapeutics presented new positive data from its Phase 3 SERENITY At-Home...
schizophrenia
Advertisement
Teva Advances Schizophrenia Therapy in Europe
TEL AVIV, Israel & PARIS, May 21, 2026 Teva Pharmaceuticals and Medincell have announced that the European Medicines Agency...
Johnson & Johnson Showcases Neuropsychiatry Data at APA 2026
TITUSVILLE, N.J., May 11, 2026 Johnson & Johnson announced the presentation of 18 new and encore abstracts highlighting the...
MapLight Therapeutics Completes Phase 2 CNS Trials Enrollment
SAN FRANCISCO & BOSTON, May 1, 2026 MapLight Therapeutics, Inc. announced the completion of enrollment in its Phase 2...
Nxera Pharma Advances Schizophrenia Drug to Phase 2
TOKYO, Japan and CAMBRIDGE, UK, April 13, 2026 Nxera Pharma Co., Ltd. announced that its partner Neurocrine Biosciences, Inc....
Advertisements
Axsome Acquires Balipodect to Expand CNS Drug Pipeline
NEW YORK, USA — April 1, 2026 Axsome Therapeutics, Inc. has announced the acquisition of exclusive global rights to...
BioXcel IGALMI sNDA Accepted by FDA for At-Home Use
NEW HAVEN, Conn., USA — April 1, 2026 BioXcel Therapeutics, Inc. announced that the U.S. Food and Drug Administration...
LB Pharma LB-102 Shows Phase 2 Cognitive Benefits in Schizophrenia
New York, USA | March 27, 2026 LB Pharmaceuticals announced new findings from its Phase 2 NOVA-1 clinical trial,...
FDA Approves BYSANTI for Bipolar I and Schizophrenia
WASHINGTON, Feb. 20, 2026 — Vanda Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved BYSANTI™...
Alto Completes Phase 2 Enrollment for CIAS Drug
MOUNTAIN VIEW, Calif., Feb. 13, 2026 — Alto Neuroscience announced completion of patient enrollment in its Phase 2 proof-of-concept...
Advertisement
